“Bimekizumab Efficacy and Safety Versus Adalimumab in Patients With Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 1, Jan. 2021, p. s15, https://doi.org/10.25251/skin.5.supp.15.